Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 22, 2013

Horizon, AstraZeneca Seek Kinase-Targeting Cancer Drugs

  • Horizon Discovery and AstraZeneca are teaming up to explore Horizon’s first-in-class kinase target program, HD-001, as a means of developing novel therapies for multiple cancer types. Horizon will receive undisclosed up-front and preclinical milestone payments, and is eligible for clinical and approval milestones totaling up to $75 million, as well as tiered royalties.

    The firms say that the HD-001 program, currently in the early stages, has the potential to be developed into a treatment based on modulation of a novel kinase. This target has been shown to be mutated in a range of cancer types including colon and lung. The target has also been shown to play a key role in K-Ras mutant tumors. K-Ras is mutated in up to 40% of all cancer types causing resistance to many of the available targeted therapeutics and as a result is associated with poor patient outcomes.

    “The program has benefitted greatly from the use of Horizon’s drug discovery toolbox to first exquisitely validate the target and then provide a range of ‘on-target’ cellular assays to support rational drug discovery,” Darrin M. Disley, Ph.D., CEO at Horizon Discovery, said. “As a result, the lead discovery effort has been rapid, resulting in a diverse portfolio of potent and selective inhibitors of the target.”

    In a separate deal said to be worth over $200 million, AZ will also be working with BIND Therapeutics to develop and commercialize a targeted and programmable cancer nanomedicine. Find out more about that deal here.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »